Form 4: Syndax Director Sells Shares Under 10b5-1 Plan

A Syndax Pharmaceuticals director executed pre-planned sales of common stock after exercising options, realizing significant gains.

Summary

• Dennis Podlesak, a Director of Syndax Pharmaceuticals Inc. (SNDX), engaged in a series of pre-planned transactions.
• The transactions involved exercising stock options at a price of $7.2 per share and subsequently selling the acquired common stock.
• On August 14, 2025, 19,200 shares were acquired via option exercise and then sold at an average price of $14.1938, with sale prices ranging from $13.30 to $14.80.
• On August 15, 2025, another 19,200 shares were acquired via option exercise and sold at an average price of $15.5421, with sale prices ranging from $14.88 to $15.91.
• On August 18, 2025, a final 19,200 shares were acquired via option exercise and sold at an average price of $15.8422, with sale prices ranging from $15.61 to $16.00.
• All sales were conducted pursuant to a Rule 10b5-1 plan, specifically covering equity grants with expiration dates prior to August 21, 2025.
• Following these transactions, the Reporting Person beneficially owns 191,763 shares of common stock directly.
• The Reporting Person retains 135,000 vested and immediately exercisable options to purchase shares of common stock, with no unvested options remaining.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive from the insider's perspective due to significant profit realization. From a market perspective, it's neutral as it's a pre-planned, routine transaction for expiring options, not necessarily signaling a change in company outlook.

Positives

• The director realized significant profits by exercising options at a lower price ($7.2) and selling shares at substantially higher market prices (ranging from $13.30 to $16.00).
• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-scheduled sales and not a reaction to new, non-public information, which can mitigate negative market perception of insider selling.
• The exercise of options and subsequent sale of shares allowed the director to monetize expiring equity grants, optimizing personal financial planning.

Negatives

• The sale of a substantial number of shares by a director, even under a 10b5-1 plan, could be interpreted by some investors as a lack of confidence in the company's near-term stock price appreciation, although this is often a routine liquidity event for insiders.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this Form 4 filing, as it primarily reports insider trading activity.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to August 21, 2025.
• Following the sales reported in this Form 4, the Reporting Person has a total of 135,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.

Industry Context

This filing represents a routine insider transaction (exercise and sell) for a director of a pharmaceutical company. Such transactions are common for executives and directors to manage their equity compensation, especially as options approach expiration. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• The execution of stock option exercises and subsequent sales under a Rule 10b5-1 plan is a standard practice for corporate insiders across various industries, including pharmaceuticals, to manage liquidity and diversify personal portfolios while adhering to insider trading regulations.
• The profit realized by the director, with sale prices significantly above the exercise price, is typical for long-term equity grants in successful companies where stock price appreciation has occurred.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be viewed neutrally or slightly negatively, but the pre-planned nature under Rule 10b5-1 mitigates concerns. It does not directly impact the company's operations or financial health.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider trading report.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction (exercise of options and subsequent sale of shares) by a director. While the director realized a significant profit, the transaction was executed under a Rule 10b5-1 plan for expiring equity grants, which typically does not signal a change in the company's fundamental outlook or future prospects. Therefore, it does not provide a strong basis for a 'buy' or 'sell' recommendation, suggesting a 'hold' is appropriate as the market impact is likely minimal and the transaction is a personal financial management event rather than a corporate strategic move.

Keywords

Syndax Pharmaceuticals, SNDX, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1 Plan, Director Stock Sale, Equity Grants, Beneficial Ownership